CRISPR
The Redemption Bet: Why Wall Street is Watching the World’s Most Controversial Scientist
He Jiankui, the jailed gene-editing scientist, is back. His return poses a critical question for investors: Is this a genius comeback or a catastrophic risk?
The Unseen Risk: Why Modern Eugenics is the Next ESG Frontier for Finance
Modern eugenics, cloaked as genetic wellness, poses a systemic risk. For finance and investors, it’s the next frontier of ESG and ethical responsibility.